keyword
https://read.qxmd.com/read/34035080/surveillance-alone-in-stage-i-malignant-ovarian-germ-cell-tumors-a-mito-multicenter-italian-trials-in-ovarian-cancer-prospective-observational-study
#1
MULTICENTER STUDY
Giorgia Mangili, Giorgio Giorda, Gabriella Ferrandina, Gennaro Cormio, Chiara Cassani, Antonella Savarese, Saverio Danese, Marco Carnelli, Francesca Maria Vasta, Anna Myriam Perrone, Giovanna Scarfone, Sandro Pignata, Francesco Legge, Francesco Raspagliesi, Gianluca Taccagni, Massimo Candiani, Giorgio Bogani, Floriana Mascilini, Alice Bergamini
OBJECTIVE: The aim of this study was to analyze the oncological outcome of stage I malignant ovarian germ cell tumors patients included in the MITO-9 study to identify those who might be recommended routine surveillance alone after complete surgical staging. METHODS: MITO-9 was a prospective observational study analyzing data collected between January 2013 and December 2019. Three groups were identified: group A included 13 patients stage IA dysgerminoma and IAG1 immature teratoma; group B included 29 patients with stage IB-C dysgerminomas, IA-C G2-G3 immature teratomas and stage IA mixed malignant ovarian germ cell tumors and yolk sac tumors; and group C included five patients (two patients with stage IC1 and one patient with stage IC2 yolk sac tumors and two patients with mixed-stage IC2 malignant ovarian germ cell tumors)...
September 2021: International Journal of Gynecological Cancer
https://read.qxmd.com/read/21277010/is-surgical-restaging-indicated-in-apparent-stage-ia-pure-ovarian-dysgerminoma-the-mito-group-retrospective-experience
#2
MULTICENTER STUDY
G Mangili, C Sigismondi, D Lorusso, G Cormio, P Scollo, R Viganò, T Gamucci, M Candiani, S Pignata
OBJECTIVE: Conservative surgery followed by platinum-based chemotherapy is considered the standard approach for pure ovarian dysgerminoma (POD), except for correctly staged IA patients. The aim of study was to evaluate the outcome of IA POD patients with incomplete surgical staging in order to define the proper management. METHODS: Data concerning primary treatment and recurrence were reviewed for 26 patients with stage IA POD treated in MITO (Multicenter Italian Trials in Ovarian Cancer) centers...
May 1, 2011: Gynecologic Oncology
https://read.qxmd.com/read/10726633/pure-dysgerminoma-of-the-ovary-a-review-of-45-well-staged-cases
#3
JOURNAL ARTICLE
A Ayhan, I Bildirici, S Günalp, K Yuce
PURPOSE: To evaluate the significance of meticulous surgical staging, and whether type of initial surgery or adjuvant therapy impacted on survival in cases of pure ovarian dysgerminoma. METHODS: Retrospective chart review of 45 patients treated for pure ovarian dysgerminoma at a single institute. Survival analysis with the Kaplan Meier and log rank test and the chi-square test for the comparison of categorical variables were used. RESULTS: Of the 45 patients subjected to a surgical staging procedure 30 (67%) had stage I disease, 2 (4%) had stage II, 9 (20%) had stage III, and 4 (9%) had stage IV pure ovarian dysgerminoma...
2000: European Journal of Gynaecological Oncology
https://read.qxmd.com/read/7651644/surgical-management-of-malignant-ovarian-germ-cell-tumors-10-years-experience-of-129-patients
#4
JOURNAL ARTICLE
F Peccatori, C Bonazzi, S Chiari, F Landoni, N Colombo, C Mangioni
OBJECTIVE: To evaluate the surgical management of ovarian germ-cell tumors treated at a single institution during the last decade. METHODS: One hundred twenty-nine patients affected by ovarian germ-cell tumors were studied retrospectively for their surgical management. Fifty-seven patients were affected by dysgerminoma, 39 by non-dysgerminoma, and 33 by pure immature teratoma. Seventy-nine patients were stage I according to International Federation of Gynecology and Obstetrics criteria, with five first referred at recurrence, 11 at stage II, 35 at stage III, and four at stage IV...
September 1995: Obstetrics and Gynecology
https://read.qxmd.com/read/679144/treatment-of-malignant-ovarian-germ-cell-tumors-response-to-vincristine-dactinomycin-and-cyclophosphamide-preliminary-report
#5
JOURNAL ARTICLE
R E Slayton, M M Hreshchyshyn, S C Silverberg, H M Shingleton, R C Park, P J DiSalia, J A Blessing
From November 1971 to November 1975, 27 patients with malignant germ cell tumors of the ovary (excluding pure dysgerminoma and tumors containing trophoblastic elements) were treated with vincristine, dactinomycin, and cyclophosphamide; 12 patients received other therapy. Fourteen tumors were pure endodermal sinus tumors, two were embryonal carcinomas, 11 were mixed germ cell tumors and 12 were immature teratomas. Of 23 patients with surgically resected disease (Stages I-IIA) only seven have failed. Median follow-up for 16 patients remaining free of disease is 24...
August 1978: Cancer
https://read.qxmd.com/read/574564/thoracotomy-in-re-staging-germinal-testis-tumors
#6
JOURNAL ARTICLE
J N Wettlaufer, R O Modarelli
In 3 patients undergoing therapy for germinal testis tumors (teratoma with choriocarcinoma, seminoma and teratocarcinoma) solitary pulmonary lesions developed consistent with metastatic tumor. After non-diagnostic medical pulmonary evaluation thoracotomy established benign lesions in each (sarcoidosis, Cryptococcus and postoperative inflammatory cyst). Surgical pathologic restaging to obviate the institution of unnecessary chemotherapy and/or radiation with its attended morbidity in such instances is stressed...
December 1979: Journal of Urology
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.